Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
GB:0QOK
Stock Latest News
Ratings
Roche: Fenebrutinib Safety Concerns Skew Risk‑Reward, Driving Sell Rating
1d ago
CHRO
Premium
The Fly
Genentech announces fenebrutinib study met primary endpoint
2d ago
CHRO
Premium
The Fly
Roche genome pricing positive for Illumina, says TD Cowen
4d ago
CHRO
ILMN
Premium
The Fly
Sarepta announces commercial launch of Elevidys in Japan
7d ago
CHRO
SRPT
Premium
The Fly
Roche announces U.S. FDA accepted NDA for giredestrant with everolimus
11d ago
CHRO
Premium
The Fly
Genentech gets FDA acceptance for giredestrant combination new drug application
12d ago
CHRO
Premium
The Fly
Genentech gets FDA approval for venclexta, acalabrutinib combination regimen
12d ago
CHRO
Premium
The Fly
Roche price target raised to CHF 340 from CHF 320 at Berenberg
12d ago
CHRO
Premium
The Fly
Roche management to meet virtually with Piper Sandler
12d ago
CHRO
Premium
The Fly
FDA to begin requiring on clinical trial
13d ago
AZN
BMY
Premium
The Fly
FDA to begin requiring one clinical trial in drug approvals
13d ago
AZN
BMY
Premium
The Fly
Roche reports MAJESTY study met primary endpoint
15d ago
CHRO
Premium
The Fly
Roche price target raised to $67 from $60 at TD Cowen
21d ago
CHRO
Premium
The Fly
Roche’s Genentech announces fenebrutinib met its primary endpoint
23d ago
CHRO
Premium
The Fly
Trump Trade: Argentina says U.S. to cut hundreds of tariffs
25d ago
BA
AZN
Premium
The Fly
TrumpRx website using technology from GoodRx, STAT says
26d ago
AZN
BMY
Premium
The Fly
Roche price target raised to CHF 295 from CHF 290 at Morgan Stanley
27d ago
CHRO
Premium
The Fly
Roche reports FY25 group sales CHF 61.52B vs. CHF 60.5B last year
1M ago
CHRO
Premium
The Fly
Roche board proposes dividend increase to CHF 9.80 per share
1M ago
CHRO
Premium
The Fly
Roche expects increase in group sales in mid single digit range for FY26
1M ago
CHRO
Premium
The Fly
Genentech announces topline results from CT388-103 trial
1M ago
CHRO
Premium
The Fly
Roche initiated with a Buy at Citi
1M ago
CHRO
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
